R. Luthra

发表

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

H. Kantarjian, A. Vega-Ruiz, J. Cortes, 2009, Leukemia research.

Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis

K. Chang, A. Malpica, R. Luthra, 2004, International Journal of Gynecologic Cancer.

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

F. Stingo, A. Bagg, P. Fox, 2014, Blood.

Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy

R. Luthra, B. Trapnell, M. Kadan, 1996, Journal of virology.

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

The World Health Organization (WHO) classification recognizes a group of myeloid neoplasms with overlapping features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms

A. Bagg, P. Fox, D. Arber, 2014 .

Cost-effectiveness of Afatinib versus Erlotinib in the First-line Treatment of Patients with Metastatic Non-small Cell Lung Cancer with EGFR Exon 19 Deletion Mutations

R. Luthra, J. Graham, S. Earnshaw, 2016 .

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012, Cancer.

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, American journal of hematology.

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, Blood.

B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease

R. Luthra, L. Medeiros, M. J. You, 2014, Modern Pathology.

Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

H. Kantarjian, J. Cortes, T. Manshouri, 2009, Clinical Cancer Research.

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2014, Cancer.

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Haematologica.

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.

H. Kantarjian, J. Cortes, R. Luthra, 2015, Blood.

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

H. Kantarjian, J. Cortes, R. Luthra, 2012, Haematologica.

Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods

A. Rashid, R. Luthra, M. Routbort, 2022, Cancers.

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

M. Konopleva, M. Andreeff, H. Kantarjian, 2015, American journal of hematology.

The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype.

A. Malpica, R. Luthra, Jinsong Liu, 2004, Oncology reports.

Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.

R. Luthra, L. Medeiros, P. Lin, 2011, American journal of clinical pathology.

Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?

Z. Estrov, H. Kantarjian, R. Luthra, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, American journal of hematology.

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia research.

Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow

T. Manshouri, R. Luthra, S. Verstovsek, 2009, Modern Pathology.

Impact of numerical variation in FMS‐like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

H. Kantarjian, R. Luthra, K. Patel, 2012, Cancer.

Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry

K. Aldape, R. Luthra, R. Goswami, 2015, The American journal of surgical pathology.

Clinical Biology of Esophageal Adenocarcinoma after Surgery Is Influenced by Nuclear Factor-κB Expression

J. Ajani, S. Swisher, Tsung-Teh Wu, 2007, Cancer Epidemiology Biomarkers & Prevention.

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, American journal of hematology.

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, International Journal of Hematology.

Molecular and clinicopathologic characterization of AML with isolated trisomy 4.

R. Luthra, L. Medeiros, Hui Yao, 2012, American journal of clinical pathology.

Sensitive PCR‐based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation

R. Luthra, S. Verstovsek, K. Patel, 2018, British journal of haematology.

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Clonal chromosomal abnormalities in Philadelphia chromosome-negative metaphases (CCA/Ph-) emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017 .

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Leukemia research.

RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia

R. Luthra, M. Routbort, K. Patel, 2015 .

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

ETV6–FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant

R. Luthra, S. Verstovsek, K. Patel, 2014, Leukemia.

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2014, Leukemia.

Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2004 .

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.